AI10 Stock Overview
A biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Biofrontera Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.80 |
| 52 Week High | US$2.18 |
| 52 Week Low | US$0.69 |
| Beta | 0.28 |
| 1 Month Change | 0% |
| 3 Month Change | -22.06% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 12.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| AI10 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.2% | 0.7% |
| 1Y | n/a | -16.8% | 8.4% |
Return vs Industry: Insufficient data to determine how AI10 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how AI10 performed against the German Market.
Price Volatility
| AI10 volatility | |
|---|---|
| AI10 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 12.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AI10's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine AI10's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 84 | Hermann Luebbert | www.biofrontera-us.com |
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.
Biofrontera Inc. Fundamentals Summary
| AI10 fundamental statistics | |
|---|---|
| Market cap | €8.22m |
| Earnings (TTM) | -€12.50m |
| Revenue (TTM) | €34.43m |
0.2x
P/S Ratio-0.7x
P/E RatioIs AI10 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AI10 income statement (TTM) | |
|---|---|
| Revenue | US$35.36m |
| Cost of Revenue | US$18.70m |
| Gross Profit | US$16.66m |
| Other Expenses | US$29.49m |
| Earnings | -US$12.84m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.66 |
| Gross Margin | 47.10% |
| Net Profit Margin | -36.31% |
| Debt/Equity Ratio | 0% |
How did AI10 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 02:28 |
| End of Day Share Price | 2024/10/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biofrontera Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bruce Jackson | Benchmark Company |
| Jonathan Aschoff | Roth MKM |